NANOBIOTIX (EPA:NANO) | Finanzwire

Basculer en Français

10482	Companies
220830	Keywords
150169	Articles
116820	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 05/21/2026 at 00:19, 12 days 1 hour ago

Nanobiotix Announces Launch of Global Follow-On Offering
Nanobiotix announces launch of global follow-on offering of approximately €75 million ($87 million) for expansion of treatment possibilities. Underwriting by Jefferies, TD Cowen, Stifel

Expansion Treatment Underwriting Global Offering NANOBIOTIX
BRIEF

published on 05/17/2026 at 16:20, 15 days 9 hours ago

Nanobiotix Presents Promising Early Phase 2 Trial Data for JNJ-1900 in Lung Cancer

Clinical Data Phase 2 Trial NBTXR3 Lung Cancer JNJ-1900
PRESS RELEASE

published on 05/17/2026 at 16:15, 15 days 9 hours ago

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Nanobiotix presents part 1 data from JNJ-1900 (NBTXR3) in lung cancer at ESTRO 2026, showing promising responses. JNJ-1900 is a novel oncology product activated by radiotherapy

NANOBIOTIX Lung Cancer JNJ-1900 Radioenhancer ESTRO 2026
BRIEF

published on 05/04/2026 at 23:34, 28 days 2 hours ago

Nanobiotix Updates Protocol for Phase 3 Cancer Study

FDA Approval Protocol Amendment Phase 3 Study NANOBIOTIX JNJ-1900
BRIEF

published on 05/04/2026 at 23:34, 28 days 2 hours ago

Nanobiotix modifies the protocol of its phase 3 cancer study

FDA Head And Neck Cancer NANOBIOTIX NANORAY-312 Modified Protocol
PRESS RELEASE

published on 05/04/2026 at 23:29, 28 days 2 hours ago

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
Nanobiotix announces FDA acceptance of protocol amendment to NANORAY-312 study for head and neck cancer, potentially accelerating global registration pathway for JNJ-1900 (NBTXR3)

Head And Neck Cancer Protocol Amendment NANOBIOTIX NBTXR3 JNJ-1900
BRIEF

published on 04/20/2026 at 08:35, 1 month 11 days ago

Nanobiotix Reveals Enhanced Bioavailability and Reduced Toxicity in Preclinical Study

Preclinical Study Bioavailability NANOBIOTIX Nanoprimer Technology LNP Immunotherapy
PRESS RELEASE

published on 04/20/2026 at 08:30, 1 month 11 days ago

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Nanobiotix presents new preclinical data at AACR 2026 showcasing Nanoprimer technology enhancing systemic bioavailability and reducing toxicity for LNP-delivered DNA immunotherapy

Preclinical Data NANOBIOTIX Nanoprimer Technology Systemic Bioavailability Toxicity Reduction
BRIEF

published on 04/07/2026 at 22:20, 1 month 24 days ago

Monthly Statement of Voting Rights and Capital of Nanobiotix

Share Capital Voting Rights Euronext Nasdaq NANOBIOTIX
BRIEF

published on 03/30/2026 at 08:35, 2 months 2 days ago

NANOBIOTIX Reveals Initial Data from Phase 2 Lung Cancer Trial

Clinical Research Phase 2 Trial NANOBIOTIX Lung Cancer JNJ-1900 (NBTXR3)

Accesswire

Published on 06/02/2026 at 00:00, 1 hour 50 minutes ago

Boron One Announces Financing
Published on 06/01/2026 at 23:57, 1 hour 53 minutes ago

Metallic Minerals Announces Bought Deal LIFE Private Placement for Gross Proceeds of C$8.0 Million
Published on 06/01/2026 at 23:05, 2 hours 45 minutes ago

Faraday Copper Strengthens Team to Support Project Advancement in Arizona
Published on 06/01/2026 at 23:00, 2 hours 50 minutes ago

CCL Industries Closing of Sleever International Acquisition
Published on 06/01/2026 at 22:30, 3 hours 20 minutes ago

Revolve to Present at the Small Cap Growth Virtual Investor Conference on June 4, 2026

View all ACCESSWIRE

EQS Group

Published on 06/01/2026 at 23:00, 2 hours 49 minutes ago

DriveNets Secures $410M Series D to Meet Surging Demand for Ethernet Fabric in Large-Scale AI Deployments
Published on 06/01/2026 at 22:05, 3 hours 44 minutes ago

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Published on 06/01/2026 at 22:05, 3 hours 45 minutes ago

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Published on 06/01/2026 at 21:20, 4 hours 30 minutes ago

Eurobattery Minerals: Loft Capital exercises conversion rights – Conversion Threshold Date reached and a total of 23,798,419 new shares to be registered
Published on 06/01/2026 at 19:00, 6 hours 49 minutes ago

Armen Pogossian Represents Armenia at Forbes Under 30 Summit China, Empowering the Next Generation of Global Entrepreneurs

Les Echos

Published on 06/01/2026 at 18:47, 7 hours 2 minutes ago

Disclosure of transactions in own shares from May 25 to May 29, 2026
Published on 06/01/2026 at 18:00, 7 hours 50 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 06/01/2026 at 17:54, 7 hours 55 minutes ago

Reporting on share buyback transactions carried out on May 28, 2026
Published on 06/01/2026 at 17:54, 7 hours 55 minutes ago

TF1 - Monthly disclosure of the total number of shares and voting rights - May 2026
Published on 06/01/2026 at 17:45, 8 hours 5 minutes ago

ENGIE secures €1 billion export financing backed by Euler Hermes

View all LES ECHOS COMFI WIRE